Johnson & Johnson’s venture capital arm is leading an $85 million investment in HistoSonics ahead of the planned commercialization of its liver cancer treatment.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,